Market Movers (8-K)
See all →NASDAQ
NeOnc Technologies announced CEO stock purchases and updated Phase 2a results for its intranasal NEO100 drug, showing an increased objective response rate.
Capital raise
NASDAQ
NeOnc Technologies Holdings, Inc. announced its CEO purchased 80,000 shares and that the FDA granted a Type B End-of-Phase meeting to discuss accelerated approval for NEO100.
Capital raise
NASDAQ
NeOnc Technologies Holdings, Inc. announced positive Q3 2026 results, showcasing advancements in its NEO100 and NEO212 clinical programs, a $15 million capital raise, and a strategic MoU with Abu Dhabi.
Capital raise
Better than expected
NASDAQ
NeOnc Technologies announced upcoming presentations of data from its intranasal NEO100 and oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology.
NASDAQ
NeOnc Technologies reports early clinical improvement in a patient treated with NEO100 and signs a Memorandum of Understanding with the Department of Health Abu Dhabi.
NASDAQ
NeOnc Technologies announced the appointment of Ali Alabedin to its Board of Directors and that CEO Amir F. Heshmatpour will speak at the Abu Dhabi Future Health Summit.
Quarterly Earnings (10-Q)
NASDAQ
NeOnc Technologies Holdings, Inc. filed its Q3 2026 Form 10-Q, detailing ongoing clinical trial expenses, substantial net losses, and significant accumulated deficit, leading to substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
NASDAQ
NeOnc Technologies Holdings, Inc. has amended its advisory agreement with AFH Holding & Advisory, LLC, establishing a new annual fee structure based on fully diluted market capitalization, while the company continues to grapple with significant operating losses and substantial doubt regarding its ability to continue as a going concern.
Worse than expected
Capital raise
NASDAQ
NEONC Technologies reported significantly increased net losses in Q3 2025 despite a NASDAQ listing and capital raises, facing substantial doubt about its going concern ability.
Worse than expected
Capital raise
Delay expected
NASDAQ
NEONC Technologies Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased operating expenses and share-based compensation, while actively pursuing new financing and strategic partnerships.
Worse than expected
Capital raise
Delay expected
NASDAQ
NeOnc Technologies Holdings reports a substantial net loss for Q1 2025, driven by increased operating expenses, including share-based compensation and advisory fees, despite completing its NASDAQ listing.
Capital raise
Worse than expected
Annual Reports (10-K)
NASDAQ
NeOnc Technologies Holdings, Inc. files an amendment to its 2025 Form 10-K to include previously omitted Part III information and updated certifications.
Delay expected
Insider Trading (Form 4)
See all →NASDAQ
Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 30,000 shares of common stock on November 13, 2026 for $5.02 per share.
NASDAQ
Thomas C Chen, CMO, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 5,016 shares of common stock on November 9, 2026.
NASDAQ
Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 70,000 shares of common stock on November 10, 2026.
NASDAQ
Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 10,000 shares of common stock on November 9, 2026 for $3.86 per share.
NASDAQ
Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 70,000 shares of common stock on November 5, 2026.
NASDAQ
Keithly Garnett, CFO of Neonc Technologies Holdings, Inc., reported a transaction in 5,000 shares of common stock on September 15, 2026.
New Public Companies (S-1)
See all →NASDAQ
NeOnc Technologies Holdings, Inc. reports significant losses and a going concern warning, while advancing multiple brain cancer drug candidates and securing recent financing.
Worse than expected
Delay expected
Capital raise
NASDAQ
NeOnc Technologies Holdings, Inc. reports significant net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidates NEO100 and NEO212 in clinical trials and acquiring new AI and 3D bioprinting platforms.
Worse than expected
Delay expected
Capital raise
NASDAQ
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on brain cancers, has filed an S-1 registration statement to facilitate the resale of shares tied to a potential $50 million equity line of credit, while disclosing significant financial losses and a 'going concern' warning from its auditors.
Delay expected
Worse than expected
Capital raise
NASDAQ
NeOnc Technologies is registering the resale of up to 5.7 million shares of its common stock by existing stockholders following its direct listing on the Nasdaq Global Market.
Worse than expected
Delay expected
Capital raise
NASDAQ
NeOnc Technologies Holdings is set to pursue a direct listing on the Nasdaq Global Market, offering 2,101,313 shares for resale by existing stockholders.
Capital raise
NASDAQ
S-1/A: NeOnc Technologies Secures Financial Advisory for Nasdaq Direct Listing and Private Placement
NeOnc Technologies has engaged RBW Capital Partners for financial advisory services related to its direct listing on Nasdaq and a private placement of common stock.
Capital raise
Schedule 13D - Activist Investments
NASDAQ
SCHEDULE 13D: Major Shareholder Discloses Significant Stake in NeOnc Technologies Following Nasdaq Direct Listing
Amir F. Heshmatpour and affiliated entities have disclosed a combined beneficial ownership of 34.3% in NeOnc Technologies Holdings, Inc. following the company's direct listing on the Nasdaq Global Market, including a cashless warrant exercise.
Schedule 13G - Passive Investments
NASDAQ
Cinctive Capital Management LP and its affiliates have reported a 9.99% beneficial ownership stake in NeOnc Technologies Holdings, Inc. as of March 31, 2026.